Last reviewed · How we verify
Antiretroviral Combinations
Antiretroviral combinations work by simultaneously targeting multiple steps of HIV replication through different drug classes to suppress viral load and prevent resistance.
Antiretroviral combinations work by simultaneously targeting multiple steps of HIV replication through different drug classes to suppress viral load and prevent resistance. Used for HIV-1 infection (treatment and/or prevention).
At a glance
| Generic name | Antiretroviral Combinations |
|---|---|
| Also known as | cART |
| Sponsor | Chang Gung Memorial Hospital |
| Drug class | Antiretroviral combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Combination antiretroviral therapy (cART) typically includes nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors, or entry inhibitors that act synergistically. By blocking HIV replication at multiple points in the viral lifecycle, combination therapy achieves sustained viral suppression, restores immune function, and reduces the emergence of drug-resistant viral strains.
Approved indications
- HIV-1 infection (treatment and/or prevention)
Common side effects
- Nausea
- Diarrhea
- Headache
- Rash
- Lipodystrophy
- Hepatotoxicity
- Lactic acidosis
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (PHASE2, PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization (NA)
- Early ART to Limit Infection and Establishment of Reservoir (PHASE2)
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
- Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (PHASE4)
- Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiretroviral Combinations CI brief — competitive landscape report
- Antiretroviral Combinations updates RSS · CI watch RSS
- Chang Gung Memorial Hospital portfolio CI